title: Ceftazidime as initial therapy in febrile patients with acute leukemia during induction chemotherapy. Leukemia Group of Middle Sweden.
abstract: We studied the efficacy of ceftazidime as initial monotherapy in 82 adult patients with acute leukemia who developed 123 febrile episodes during induction chemotherapy. 88% of the patients survived their febrile episode(s), whereas 10% died of infection. When assessed at 72 h after initiation of treatment (early evaluation), 43/123 episodes (35%) had been successfully treated with ceftazidime. These 43 favourable responses were seen in 15/47 (32%) microbiologically documented infections, 20/46 (43%) clinically defined infections, and 8/30 (27%) fever of unknown origin (FUO). At the resolution of fever (late evaluation) 115 episodes were evaluable, and 48% had responded successfully to ceftazidime. Successful treatment was most frequently observed in FUO, 18/29 (62%). In contrast, only 19/44 (43%) microbiologically documented infections and 18/42 (43%) clinically defined infections were cured during ceftazidime treatment. In bacteremia the response rate was only 8/26 (31%). Thus, this study shows that although ceftazidime can be safely used for initial empirical monotherapy in neutropenic leukemia patients, the need for therapy modification is high and few patients with serious infections are cured with ceftazidime alone.
authors.affiliation: Department of Medicine, Stockholm Söder Hospital, Sweden.
authors.forename: J
authors.initials: J
authors.lastname: Samuelsson
authors.forename: B
authors.initials: B
authors.lastname: Lönnqvist
authors.forename: J
authors.initials: J
authors.lastname: Palmblad
authors.forename: G
authors.initials: G
authors.lastname: Grimfors
authors.forename: M
authors.initials: M
authors.lastname: Järnmark
authors.forename: R
authors.initials: R
authors.lastname: Lerner
authors.forename: P
authors.initials: P
authors.lastname: Ljungman
authors.forename: C
authors.initials: C
authors.lastname: Nyström-Rosander
authors.forename: G
authors.initials: G
authors.lastname: Oberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy; D002442:Ceftazidime / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D005334:Fever / Q000188:drug therapy* / Q000209:etiology; D005335:Fever of Unknown Origin / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D002442:Ceftazidime; D013866:Thioguanine; D003630:Daunorubicin